Kraj: Irlandia
Język: angielski
Źródło: HPRA (Health Products Regulatory Authority)
Omeprazole magnesium
AstraZeneca UK Limited
A02BC; A02BC01
Omeprazole magnesium
40 milligram(s)
Gastro-resistant tablet
Product subject to prescription which may be renewed (B)
Proton pump inhibitors; omeprazole
Marketed
1999-09-17
BODY TEXT SIZE 9.0 pt SMALLEST TEXT SIZE 6.0 pt 565631-A02 10-04-17 PS10339 AZL4004A 7514 NK Losec MUPS 10mg, 20mg, 40mg Leaflet: Patient Ireland-Malta Black Technical Info Profile Package leaflet: Information for the patient Losec MUPS 10 mg gastro-resistant tablets Losec MUPS 20 mg gastro-resistant tablets Losec MUPS 40 mg gastro-resistant tablets omeprazole Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What Losec is and what it is used for 2. What you need to know before you take Losec 3. How to take Losec 4. Possible side effects 5. How to store Losec 6. Contents of the pack and other information 1. What Losec is and what it is used for Losec gastro-resistant tablets contains the active substance omeprazole. It belongs to a group of medicines called ‘proton pump inhibitors’. They work by reducing the amount of acid that your stomach produces. Losec is used to treat the following conditions: In adults: • ‘Gastro-oesophageal reflux disease’ (GORD). This is where acid from the stomach escapes into the gullet (the tube which connects your throat to your stomach) causing pain, inflammation and heartburn. • Ulcers in the upper part of the intestine (duodenal ulcer) or stomach (gastric ulcer). • Ulcers which are infected with bacteria called ‘_Helicobacter pylori_’. If you have this condition, your doctor may also prescribe antibiotics to treat the infection and allow the ulcer to heal. • Ulcers caused by medicines called NSAIDs (Non-Steroidal Anti-Inflammatory Drugs). Losec can al Przeczytaj cały dokument
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Losec MUPS 40 mg gastro-resistant Tablets. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 40 mg: Each gastro-resistant tablet contains 41.3 mg omeprazole magnesium equivalent to 40 mg omeprazole. Excipient(s) with known effect 40 mg: Each gastro-resistant tablet contains 39–41 mg sucrose. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Gastro-resistant tablet. Losec 40 mg gastro-resistant tablets: Dark red-brown, oblong, biconvex, film-coated tablets, engraved with on one side and 40 mg and a score on the other side containing enteric coated pellets_._ 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Losec gastro-resistant tablets are indicated in: Adults Treatment of duodenal ulcers Prevention of relapse of duodenal ulcers Treatment of gastric ulcers Prevention of relapse of gastric ulcers In combination with appropriate antibiotics,_ Helicobacter pylori (H. pylori)_ eradication in peptic ulcer disease Treatment of NSAID - associated gastric and duodenal ulcers Prevention of NSAID - associated gastric and duodenal ulcers in patients at risk Treatment of reflux oesophagitis Long-term management of patients with healed reflux oesophagitis Treatment of symptomatic gastro-oesophageal reflux disease Treatment of Zollinger-Ellison syndrome Paediatric use _Children over 1 year of age and_ _10 kg_ Treatment of reflux oesophagitis Symptomatic treatment of heartburn and acid regurgitation in gastro-oesophageal reflux disease _Children and adolescents over 4 years of age_ In combination with antibiotics in treatment of duodenal ulcer caused by_ H. pylori_ 4.2 POSOLOGY AND METHOD OF ADMINISTRATION H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ _ Przeczytaj cały dokument